Streamlining Cell Therapy Downstream Processing by Evaluating Platform Options & Integrating Automation for Commercial Transition

• Identifying which downstream process parameters can be modified versus fixed constraints inherent to cell therapy product profiles to focus optimization efforts effectively
• Evaluating existing downstream platform landscape including module features, pros and cons across different cell therapy situations to select best-fit technologies
• Implementing automation considerations at each development stage to enable seamless platform transitions and prevent costly impacts during commercial scale-up

Speakers:

Zhuoer Lin

Associate Director

Johnson & Johnson